ABCG2 and non-small cell lung carcinoma: In preclinical pharmacokinetic studies, it has been evaluated for many of the various targeted NSCLC oncoprotein inhibitors whether they are a transported substrate for the ABCB1 and ABCG2 transporters, using knockout mice.